Fibromyalgia - Market Insight, Epidemiology and Market Forecast - 2027

Fibromyalgia - Market Insight, Epidemiology and Market Forecast - 2027

  • Pages: 120
  • Geography: Global
  • Delivery Timeline: 5 Business Days
  • Publication: Jan, 2018
  • SKU: DIMI0282
  • Single User License
    (20% Off)
    $6,250.00
    $5000
  • Site License
    (30% Off)
    $12,500.00
    $8750
  • Global License
    (40% Off)
    $18,750.00
    $11250
Request Sample

Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Address*  
Message*  
X

Request Sample Pages

Request Before Buy
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Inquire Before Buy

Send Friend
Name*  
Email ID*  
Mobile*  
Company*  
Message*  
X

Send to Friend

DelveInsight’s ‘Fibromyalgia  - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Fibromyalgia in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Fibromyalgia from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

• The United States

• EU5 (Germany, France, Italy, Spain and the United Kingdom)

• Japan

Study Period: 2016-2027
Fibromyalgia - Disease Understanding and Treatment Algorithm
Fibromyalgia (FM) is a common and complex chronic pain disorder that affects people physically, mentally and socially. It is characterized by chronic widespread pain, multiple tender points, abnormal pain processing, sleep disturbances, fatigue and often psychological distress. Fibromyalgia is mainly caused due to genetic conditions but the actual cause is still unknown. Most researchers agree that FM is a disorder of central processing with neuroendocrine/neurotransmitter dysregulation.
The DelveInsight Fibromyalgia market report gives the thorough understanding of the Fibromyalgia by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Fibromyalgia in the US, Europe, and Japan.

Fibromyalgia Epidemiology
The Fibromyalgia epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology scenario of Fibromyalgia in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
According to National Fibromyalgia Association, the disorder affects an estimated 10 million people in the U.S. and an estimated 3-6% of the world population. The diagnosis is usually made between the ages of 20 to 50 years, but the incidence rises with age so that by age 80, approximately 8% of adults meet the American College of Rheumatology [ACR] classification criteria of fibromyalgia.

Fibromyalgia Drug Chapters
This segment of the Fibromyalgia report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Although there is no cure for Fibromyalgia, the current treatment focusses on reduction of the symptoms. Based on the drug classes, the Fibromyalgia therapeutic market is segmented as Antidepressants (Venlafaxine, Duloxetine HCl, Milnacipran HCl), Anticonvulsants (Pregabalin, Gabapentin), Muscle relaxants and Analgesics. While drug treatments are available for the symptoms of fibromyalgia, yet their efficacy varies from patient to patient, and significant side effects can limit benefits or preclude use of these medications. Thus, there is a continued need for additional effective and tolerable treatment options for patients to improve their daily functioning.

Fibromyalgia Market Outlook
The Fibromyalgia market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. 
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. 
Key players such as Aptinyx, Astellas Pharma and Innovative med concepts are involved in developing therapies for Fibromyalgia. Expected launch of emerging therapies such as NYX-2925 (Aptinyx), ASP0819 (Astellas Pharma) and IMC-1 (Innovative med concepts) will significantly impact the Fibromyalgia market during the study period (2016-2027).

Fibromyalgia Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Fibromyalgia Report Insights

• Patient Population

• Therapeutic Approaches

• Pipeline Analysis

• Market Size and Trends

• Market Opportunities

• Impact of upcoming Therapies

Fibromyalgia Report Key Strengths

• 10 Years Forecast

• 7MM Coverage 

• Epidemiology Segmentation

• Sub-type Segmentation

• Key Cross Competition 

• Highly Analyzed Market

• Drugs Uptake

Fibromyalgia Report Assessment

• Current Treatment Practices

• Unmet Needs

• Pipeline Product Profiles

• Market Attractiveness

• Market Drivers and Barriers

Key Benefits

• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Fibromyalgia market

• Organize sales and marketing efforts by identifying the best opportunities for Fibromyalgia market

• To understand the future market competition in the Fibromyalgia market.

1. Report Introduction
2. Fibromyalgia Market Overview at a Glance
2.1. 7 Major Market Size of Fibromyalgia in 2017
2.2. 7 Major Market Size of Fibromyalgia in 2027
3. Disease Background and Overview: Fibromyalgia 
3.1. Introduction
3.2. Causes
3.3. Pathophysiology
3.4. Symptoms
3.5. Risk Factor
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Assumptions and Caveats
4.2. 7MM Prevalent cases of Fibromyalgia (2016-2027)
4.3. 7MM Gender specific  prevalence of Fibromyalgia (2016-2027) 
4.4. 7MM Diagnosed and Treatable Cases of Fibromyalgia (2016-2027)
5. Fibromyalgia: Country- Wise Epidemiology
5.1. United States
5.1.1. Prevalent cases of Fibromyalgia in the United States (2016-2027)
5.1.2. Gender specific  prevalence of Fibromyalgia in the United States (2016-2027)
5.1.3. Diagnosed and Treatable Cases of Fibromyalgia in the United States (2016-2027)
5.2. EU-5
5.2.1. Germany
5.2.1.1. Prevalent cases of Fibromyalgia in Germany (2016-2027)
5.2.1.2. Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
5.2.1.3. Diagnosed and Treatable Cases of Fibromyalgia in Germany (2016-2027)
5.2.2. France
5.2.2.1. Prevalent cases of Fibromyalgia in France (2016-2027)
5.2.2.2. Gender specific  prevalence of Fibromyalgia in France (2016-2027)
5.2.2.3. Diagnosed and Treatable Cases of Fibromyalgia in France (2016-2027)
5.2.3. Italy
5.2.3.1. Prevalent cases of Fibromyalgia in Italy (2016-2027)
5.2.3.2. Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
5.2.3.3. Diagnosed and Treatable Cases of Fibromyalgia in Italy (2016-2027)
5.2.4. Spain
5.2.4.1. Prevalent cases of Fibromyalgia in Spain (2016-2027)
5.2.4.2. Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
5.2.4.3. Diagnosed and Treatable Cases of Fibromyalgia in Spain (2016-2027)
5.2.5. United Kingdom
5.2.5.1. Prevalent cases of Fibromyalgia in United Kingdom (2016-2027)
5.2.5.2. Gender specific  prevalence of Fibromyalgia in United Kingdom (2016-2027)
5.2.5.3. Diagnosed and Treatable Cases of Fibromyalgia in United Kingdom (2016-2027)
5.3. Japan
5.3.1. Prevalent cases of Fibromyalgia in Japan (2016-2027)
5.3.2. Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
5.3.3. Diagnosed and Treatable Cases of Fibromyalgia in Japan (2016-2027)
6. Treatment & Medical Practices
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. Marketed drugs
7.1. Duloxetine: Eli Lilly
7.1.1. Product Description
7.1.2. Mechanism of action
7.1.3. Regulatory milestones
7.1.4. Other Development Activities
7.1.5. Safety and Efficacy
7.1.6. Advantages and Disadvantages
7.1.7. Product Profile
7.2. Milnacipran: Forest Pharmaceuticals
7.2.1. Product Description
7.2.2. Mechanism of action
7.2.3. Regulatory milestones
7.2.4. Other Development Activities
7.2.5. Safety and Efficacy
7.2.6. Advantages and Disadvantages
7.2.7. Product Profile
To be continued in the report...
8. Emerging Therapies
8.1. Key Cross Competition
8.2. NYX-2925: Aptinyx
8.2.1. Regulatory Milestones
8.2.2. Clinical Development
8.2.3. Product Profile
8.2.4. Clinical Pipeline Activity
8.2.4.1. Ongoing Trials Information
8.2.4.2. Clinical Trial by Phase
8.3. ASP0819: Astellas Pharma
8.3.1. Regulatory Milestones
8.3.2. Clinical Development
8.3.3. Product Profile
8.3.4. Clinical Pipeline Activity
8.3.4.1. Ongoing Trials Information
8.3.4.2. Clinical Trial by Phase
8.4. IMC-1: Innovative med concepts
8.4.1. Regulatory Milestones
8.4.2. Clinical Development
8.4.3. Product Profile
8.4.4. Clinical Pipeline Activity
8.4.4.1. Ongoing Trials Information
8.4.4.2. Clinical Trial by Phase
To be continued in the report…
9. Fibromyalgia: Market Size
9.1. Key Findings
9.2. Total 7MM Fibromyalgia Market Analysis 
9.2.1. Overview of Total Fibromyalgia Market 
9.2.2.  Market size of Fibromyalgia by 7MM (2016-2027)
10. 7MM Fibromyalgia: Country-Wise Market Analysis
10.1. United States
10.1.1. Total Market Size of Fibromyalgia
10.1.2. Market Size of Fibromyalgia by Therapies
10.2. Germany
10.2.1. Total Market Size of Fibromyalgia
10.2.2. Market Size of Fibromyalgia by Therapies
10.3. France
10.3.1. Total Market Size of Fibromyalgia
10.3.2. Market Size of Fibromyalgia by Therapies
10.4. United Kingdom
10.4.1. Total Market Size of Fibromyalgia
10.4.2. Market Size of Fibromyalgia by Therapies
10.5. Spain
10.5.1. Total Market Size of Fibromyalgia
10.5.2. Market Size of Fibromyalgia by Therapies
10.6. Italy
10.6.1. Total Market Size of Fibromyalgia
10.6.2. Market Size of Fibromyalgia by Therapies
10.7. Japan
10.7.1. Total Market Size of Fibromyalgia
10.7.2. Market Size of Fibromyalgia by Therapies
11. Report Methodology
11.1. Sources Used
12. DelveInsight Capabilities
13. Disclaimer
14. About DelveInsight

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Table 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Table 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Table 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Table 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Table 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Table 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Table 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Table 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Table 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Table 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Table 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Table 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Table 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Table 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Table 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Table 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Table 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Table 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Table 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Table 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Table 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Table 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Table 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Table 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Table 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Table 26 NYX-2925, Clinical Trials by Zone, 2018
Table 29 IMC-1, Clinical Trials by Recruitment status, 2018
Table 30 IMC-1, Clinical Trials by Zone, 2018
Table 31 ASP0819, Clinical Trials by Recruitment status, 2018
Table 32 ASP0819, Clinical Trials by Zone, 2018
Table 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Table 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Table 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Table 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Figure 1 7MM Prevalent cases of Fibromyalgia (2016-2027)
Figure 2 7MM Gender specific  prevalence of Fibromyalgia (2016-2027)
Figure 3 7MM Diagnosed and Treatable cases of Fibromyalgia (2016-2027)
Figure 4 Prevalent cases of Fibromyalgia in the US (2016-2027)
Figure 5 Gender specific  prevalence of Fibromyalgia in the US (2016-2027)
Figure 6 Diagnosed and Treatable Cases of Fibromyalgia in the US (2016-2027)
Figure 7 Prevalent cases of Fibromyalgia in Germany (2016-2027)
Figure 8 Gender specific  prevalence of Fibromyalgia in Germany (2016-2027)
Figure 9 Diagnosed and Treatable cases of Fibromyalgia in Germany (2016-2027)
Figure 10 Prevalent cases of Fibromyalgia in France (2016-2027)
Figure 11 Gender specific  prevalence of Fibromyalgia disease in France (2016-2027)
Figure 12 Diagnosed and Treatable cases of Fibromyalgia in France (2016-2027)
Figure 13 Prevalent cases of Fibromyalgia in Italy (2016-2027)
Figure 14 Gender specific  prevalence of Fibromyalgia in Italy (2016-2027)
Figure 15 Diagnosed and Treatable cases of Fibromyalgia in Italy (2016-2027)
Figure 16 Prevalent cases of Fibromyalgia in Spain (2016-2027)
Figure 17 Gender specific  prevalence of Fibromyalgia in Spain (2016-2027)
Figure 18 Diagnosed and Treatable cases of Fibromyalgia in Spain (2016-2027)
Figure 19 Prevalent cases of Fibromyalgia in the UK (2016-2027)
Figure 20 Gender specific  prevalence of Fibromyalgia in the UK (2016-2027)
Figure 21 Diagnosed and Treatable cases of Fibromyalgia in the UK (2016-2027)
Figure 22 Prevalent cases of Fibromyalgia in Japan (2016-2027)
Figure 23 Gender specific  prevalence of Fibromyalgia in Japan (2016-2027)
Figure 24 Diagnosed and Treatable cases of Fibromyalgia in Japan (2016-2027)
Figure 25 NYX-2925, Clinical Trials by Recruitment status, 2018
Figure 26 NYX-2925, Clinical Trials by Zone, 2018
Figure 29 IMC-1, Clinical Trials by Recruitment status, 2018
Figure 30 IMC-1, Clinical Trials by Zone, 2018
Figure 31 ASP0819, Clinical Trials by Recruitment status, 2018
Figure 32 ASP0819, Clinical Trials by Zone, 2018
Figure 33 7 Major Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 34 Region wise Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 35 7MM-Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 36 United States Market of Fibromyalgia Size in USD, Million (2016-2027)
Figure 37 United States Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 38 Germany Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 39 Germany Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 40 France Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 41 France Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 42 Italy Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 43 Italy Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 44 Spain Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 45 Spain Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 46 United Kingdom Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 47 United Kingdom Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027)
Figure 48 Japan Market Size of Fibromyalgia in USD, Million (2016-2027)
Figure 49 Japan Market Size of Fibromyalgia by Therapy in USD, Million (2016-2027) 

 

Key Companies
Speak to Analyst
Name*  
Email ID*  
Mobile*  
Company*  
Country*  
Zip Code*  
Specific Filed of Interest*  
X

Speak to Analyst

+1(919)321-6187

Related Reports

Contact Us

Phone

India: +91-11-45689769, +91-9650213330

Email

info@delveinsight.com

Address

New Delhi-110075, India

Address

304 S. Jones Blvd #2432, Las Vegas NV 89107

Phone

Outside India: +1(919)321-6187

Latest Tweets

Copyright © 2018 Delveinsight.